SBIR/STTR Research Award

Organ Specific Damage Assessment Biomarker Assays

Award identifier 6872e0a02a5b2ad7b58b8193f5e024b773d853313bc42356e2c8d537105e7770Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$710,033

Program and phase

SBIR · Phase II

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
OXFORD BIOMEDICAL RESEARCH, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
NQTNG8N1R3Q8
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Biomarkers that accurately reflect acute and/or past exposure to harmful agents are crucial in any study aiming to reduce the incidence of diseases resulting from environmental chemicals or other exposures. The biomarkers evaluated to date in biological fluids with relatively non-invasive access generally lack organ specificity and are not sensitive enough to detect mild damage and/or damage that occurred in the past In Phase I we employed a novel approach to identify unique biomarkers of acute exposure to toxicants in two rodent models. Following administration of toxicants in rat liver and lung damage models, we immunopurifed oxidized organ specific proteins from serum using mini prep affinity resins prepared with antibodies against three oxidized amino acids, chlorotyrosine, nitrotyrosine and methanionine sulfoxide. We then identified those proteins that were liver or lung specific by the proteomics approach of 2D gel separation, computerized and robotic spot picking, in-gel digests and MALDI/MS analysis. We succeeded in identifying several such damage biomarkers in serum derived from both lung and liver after administration of ozone and CCl4. Having demonstrated proof of concept in Phase I, in Phase II we propose to expand our studies to multiple organ systems, develop and validate highly specific sandwich immunoassays for oxidized protein biomarkers specific for various tissues, demonstrate proof of diagnostic concept and develop a prototype miniarray consisting of multiple organ specific oxidized protein biomarker ELISAs. Our long-term objective is to develop miniarrays of rat and human, organ-specific, damage assessment biomarkers. In a broad sense these arrays can serve the toxicology industry for both environmental agent exposure assessment and for drug development toxicology studies in animals and humans. In addition, they could be useful in clinical settings for the identification and monitoring of diseases in which diagnosis is difficult or equivocal.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

44 SBIR/STTR records share this UEI (1985–2021). Reported award amounts total $7,846,299. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Agriculture, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.